Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-TMPRSS6-Lrx Administered Subcutaneously to Healthy Volunteers

Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-TMPRSS6-Lrx Administered Subcutaneously to Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs IONIS-TMPRSS6-LRx (Primary)
  • Indications Thalassaemia
  • Focus Adverse reactions
  • Sponsors Ionis Pharmaceuticals
  • Most Recent Events

    • 04 Dec 2018 Results assessing safety of IONIS-TMPRSS6-LRx in healthy volunteers, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 31 Aug 2018 Biomarkers information updated
    • 31 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top